RNTCP or the Revised National Tuberculosis Control Program is the state-run tuberculosis control initiative of the Government of India. It incorporates the principles of directly observed treatment-shortcourse (DOTS), the global TB control strategy of the World Health Organization. The program provides, free of cost, quality anti-tubercular drugs across the country through the numerous Primary Health Centres and the growing number of private-sector DOTS-providers
Need for a Revised Strategy 
India has had an on-going National TB Program, NTP since 1962.
Program reviews showed that only 30% of estimated tuberculosis patients were diagnosed and only 30 percent of those were treated successfully.
Based on the findings and recommendations of the review in 1992, the GOI evolved a revised strategy and launched the Revised National TB Control Programme (RNTCP) in the country.
Components of RNTCP 
The five principal components of DOTS are:
- Political and administrative commitment
- Case detection by sputum smear microscopy
- Uninterrupted supply of high-quality anti-TB drugs
- Standardized treatment regimens with directly observed treatment for at least the first two months
- Systematic monitoring and accountability
Diagnosis of Pulmonary TB under RNTCP 
Sputum smear microscopy, using the Ziehl-Neelsen staining technique, is employed as the standard case-finding tool. Two sputum samples are collected over two days (as spot-morning/morning-spot) from chest symptomatics (patients with presenting with a history of cough for two weeks or more) to arrive at a diagnosis. In addition to the test's high specificity, the use of two samples ensures that the diagnostic procedure has a high (>99%) test sensitivity as well.
As a national health program, RNTCP pays more attention to the sputum-positive pulmonary tuberculosis patients (who are likely to spread the disease in the community) than people with other, non-pulmonary forms of the disease.
Treatment Categories and Drug Regimens 
Standardized treatment regimens are one of the pillars of the DOTS strategy
Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, and Streptomycin are the primary antitubercular drugs used. Most DOTS regimens have thrice-weekly schedules and typically last for 6 to 8 months, with an initial intensive phase and a continuation phase.
Based on the nature/severity of the disease and the patient's exposure to previous anti-tubercular treatments, RNTCP classifies tuberculosis patients into two treatment categories.
New sputum smear-positive,
New sputum smear-negative,
New extrapulmonary tuberculosis,
Sputum smear-positive relapse,
Sputum smear-positive failure,
Sputum smear-positive treatment after default,
|2H3R3Z3E3 + 4H3R3||2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3|
|2 months Intensive phase + 4 months continuation phase
Four drugs at Thrice-weekly Schedule for 2 months Intensive phase & Two drugs at Thrice-Weekly Schedule for remaining 4 months continuation phase.
|3 months Intensive phase + 5 months continuation phase
Five drugs at Thrice-weekly Schedule for initial 2 months followed by Four drugs for next 1 month Intensive phase.Three drugs at Thrice-weekly Schedule for remaining 5 months continuation phase.
- Patients who weigh 60kg or more receive additional Rifampicin 150mg.
- Patients who are more than 50 years old receive Streptomycin 500mg. Patients who weigh less than 30kg receive drugs as per Pediatric weight band boxes according to body weight.
*New categories includes former Categories I & III
**Previously treated is former Category II
# Others include patients who are Sputum Smear-Negative or who have Extra-pulmonary disease who can have recurrence or resonance.
PPP - Public Private Patrnership under RNTCP 
In India, a sizable proportion of the people with symptoms suggestive of pulmonary tuberculosis approach the private sector for their immediate health care needs. There is need for regularizing the varied anti-tubercular treatment regimens used by general practitioners and other private sector players.The treatment carried out by the private practitioners vary from that of the RNTCP treatment.So once treatment is started in the usual way carried out by the private sector,it is difficult for the patient to change to the RNTCP panel.Studies have shown that faulty anti TB prescriptions in private sector in India ranges from 50 to 100 % and this is a mater of concern for the healthcare services in TB currently being provided by the largely unregulated private sector in India.
Second Phase of RNTCP 
In the first phase of RNTCP (1998–2005), the programme’s focus was on ensuring expansion of quality DOTS services to the entire country. The future holds a different set of challenges including MDR TB and HIV/TB
The RNTCP has now entered its second phase, approved for a period of five years from October 2006 to September 2011, in which the programme aims to firstly consolidate the gains made to date, to widen services both in terms of activities and access, and to sustain the achievements. The second phase aims to maintain at least a 70% case detection rate of new smear positive cases as well as maintain a cure rate of at least 85%. This needs to be done in order to achieve the TB-related targets set by the Millennium Development Goals for 2015 and to achieve TB control in the longer term.
See also 
- Public health system in India
- Epidemiology of tuberculosis
- Tuberculosis treatment
- Tuberculosis diagnosis
- The Global Alliance for TB Drug Development
- Stop TB Strategy
- Global Plan to Stop Tuberculosis
- Multi-drug-resistant tuberculosis
-  Tuberculosis Control India's Homepage on RNTCP
- TRC Chennai Tuberculosis Research Center, Chennai
- NTI Bangalore The National Tuberculosis Institute, Bangalore
- StopTB The Stop Tuberculosis Partnership Website
- History of TB Control in India
- WHO Page on TB WHO's Global TB Programme
- What is DOTS? A guide to Understanding the WHO-recommended TB Control Strategy -1999
- RNTCP at a Glance
- Tuberculosis Control in India
- RNTCP Annual Report, 2007 Status Reports 2007
- Anurag Bhargava, Lancelot Pinto, Madhukar Pai (2011). "Mismanagement of tuberculosis in India: Causes, consequences, and the way forward". Hypothesis 9 (1): e7.
- Gyanshankar Mishra, Jasmin Mulani (2013). "Tuberculosis Prescription Practices In Private And Public Sector In India". National Journal of Integrated Research in Medicine 4 (4): 71–76.